Inhibrx Inc. announced that the European Commission (“EC”), based on a positive opinion issued by the European Medicines Agency (“EMA”), has granted orphan medicinal product designation to INBRX-109 for the treatment of chondrosarcoma.
https://www.pharmalive.com/wp-content/uploads/2022/08/inhibrx_Logo.jpg4001200PR Newswirehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngPR Newswire2022-08-15 16:05:252022-08-16 11:54:13European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma
